Total
0
Shares
Theratechnologies Inc. (TSX:TH) announces new hires to support its commercial and pipeline assets
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Theratechnologies welcomes Mr. John Leasure as Global Commercial Officer and Mr. Peter Kowal as Vice President, HIV-U.S. Commercial Operations
  • Mr. Leasure spent 30 years at Pfizer in the United States and Canada
  • Mr. Leasure will oversee Theratechnologies’ HIV-U.S. business
  • Mr. Kowal has spent 23 years in various pharmaceutical sales and marketing positions, specializing in the areas of HIV and endocrinology
  • Mr. Kowal will oversee sales, access and reimbursement efforts while working very closely with marketing
  • Theratechnologies (TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies
  • Theratechnologies Inc. (TH) is up 1.76 per cent, trading at C$4.62 per share at 3pm ET

Theratechnologies Inc. (TH) has added two new senior resources to support the growth and development of its commercial and pipeline assets.

Theratechnologies welcomes Mr. John Leasure as Global Commercial Officer and Mr. Peter Kowal as Vice President, HIV-U.S. Commercial Operations.

“Both John and Peter bring important capabilities that are needed to bring Theratechnologies to our next stage of growth. I am very pleased that we were able to attract such talented and experienced individuals with expertise across HIV, endocrinology, and oncology. I look forward to their contributions toward the growth of our commercial assets and the development of our pipeline.

On behalf of the entire team at Theratechnologies, I want to extend the warmest welcome to our new colleagues,” said Paul Lévesque, President and Chief Executive Officer, Theratechnologies.

Mr. Leasure spent 30 years at Pfizer in the United States and Canada where he held increasingly senior functions in the Anti-infectives, Inflammation Immunology and Oncology businesses.

Most recently, Mr. Leasure led Pfizer’s Oncology business unit in Canada where, under his leadership, the business experienced unprecedented growth and launched more than 10 new products.

In his new function, Mr. Leasure will oversee Theratechnologies’ HIV-U.S. business and will also develop global capabilities in Marketing, Pricing & Reimbursement, Analytics, Manufacturing, Sourcing and Drug Development as well as New Project Planning.

Mr. Leasure holds a B.A. in Management from Gettysburg College. 

Mr. Kowal has spent 23 years in various pharmaceutical sales and marketing positions, specializing in the areas of HIV and endocrinology.

Most recently, he was U.S. Head, Sales, Marketing, Strategy and Operations at Merck KGaA-EMD Serono, Inc.

Mr. Kowal brings significant expertise to the company’s HIV-U.S. business and will oversee sales, access and reimbursement efforts while working very closely with marketing to ensure optimal deployment of resources.

Mr. Kowal holds a Master of Education from Temple University and a B.Sc. in Biology from Ithaca College.

Theratechnologies (TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

Theratechnologies Inc. (TH) is up 1.76 per cent, trading at C$4.62 per share at 3pm ET.

More From The Market Herald
HempFusion (TSX:CBD.U) announces US$2M private placement

" HempFusion (TSX:CBD.U) increases private placement

HempFusion Wellness (CBD.U) has increased the size of its previously announced non-brokered private placement to over US$2,500,000.
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

" Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.